Literature DB >> 19469471

Tailored PEG for rh-G-CSF analogue site-specific conjugation.

Stefano Salmaso1, Sara Bersani, Anna Scomparin, Francesca Mastrotto, Rodolfo Scherpfer, Giancarlo Tonon, Paolo Caliceti.   

Abstract

A new end-tailored monomethoxypoly(ethylene glycol) (PEG) for site-directed protein conjugation was synthesized according to a three-step procedure: (1) linear 20 kDa PEG-NH(2) was conjugated to 12-(Boc-amino)dodecanoic acid; (2) PEG-NHCO(CH(2))(11)-Boc was deprotected by TFA treatment; (3) PEG-NHCO(CH(2))(11)-NH(2) was conjugated to 6-maleimidohexanoic acid to yield PEG-NHCO-(CH(2))(11)-NHCO(CH(2))(5)-Mal (PEG-C(18)-Mal). The chemical intermediates as well as the final product were purified by solvent precipitation/extraction and characterized by (1)H NMR spectroscopy and colorimetric analysis. The synthesis procedure yielded over 90% activated product [PEG-NHCO-(CH(2))(11)-NHCO(CH(2))(5)-Mal/PEG-NH(2) molar ratio, %]. Both PEG-C(18)-Mal and the commercial maleimido activated 20 kDa linear PEG (PEG-Mal) were used for conjugation to (17)Cys of recombinant human granulocyte colony stimulating factor (rh-G-CSF). Under denaturing conditions, at pH 7.0, both activated PEGs yielded over 90% protein conjugation. Under native conditions, about 55% and 7% PEGylated protein were obtained with PEG-C(18)-Mal and PEG-Mal, respectively. Circular dichroism analysis showed that the PEGylation does not induce detectable alteration of the protein secondary structure. On the other hand, the PEGylation conditions were found to affect significantly the protein stability. The derivatives obtained either with the two polymers by unfolding/refolding process or with PEG-Mal under native conditions displayed rapid aggregation with half-life ranging from 30 to 90 min. The derivative obtained with PEG-NHCO-(CH(2))(11)-NHCO(CH(2))(5)-Mal in the absence of guanidinium chloride displayed remarkably higher stability with aggregation half-life of about 60 h.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19469471     DOI: 10.1021/bc9000432

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  4 in total

Review 1.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

2.  Elucidation of PEGylation site with a combined approach of in-source fragmentation and CID MS/MS.

Authors:  Xiaojun Lu; P Clayton Gough; Michael R DeFelippis; Lihua Huang
Journal:  J Am Soc Mass Spectrom       Date:  2010-01-25       Impact factor: 3.109

3.  Development of quinic acid-conjugated nanoparticles as a drug carrier to solid tumors.

Authors:  Zohreh Amoozgar; Joonyoung Park; Qingnuo Lin; Johann H Weidle; Yoon Yeo
Journal:  Biomacromolecules       Date:  2013-06-05       Impact factor: 6.988

4.  Biophysical characterization of Met-G-CSF: effects of different site-specific mono-pegylations on protein stability and aggregation.

Authors:  Antonino Natalello; Diletta Ami; Maddalena Collini; Laura D'Alfonso; Giuseppe Chirico; Giancarlo Tonon; Silvia Scaramuzza; Rodolfo Schrepfer; Silvia Maria Doglia
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.